+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07732400

Study Evaluating VV-14303 Gene Therapy for Adults With Metabolic Dysfunction-associated Steatohepatitis MASH Using Dose Escalation to Assess Safety and Efficacy

Led by Kriya Therapeutics, Inc. · Updated on 2026-09-01

56

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating VV-14303, a gene therapy using an adeno-associated virus vector to deliver Fibroblast Growth Factor 21 FGF21, for adults with Metabolic Dysfunction-associated Steatohepatitis MASH. This Phase 12 study aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of VV-14303 in this condition. The trial is a first-in-human, multi-arm, dose-escalation study conducted by Kriya Therapeutics, Inc.

CONDITIONS

Brief Title

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

Research Team

V

VP, Medical Affairs

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here